Overview


According to FutureWise analysis the market for eosinophilic esophagitis (eoe) in 2023 is US$ 140 billion, and is expected to reach US$ 1022.76 billion by 2031 at a CAGR of 28.22%.

Eosinophilic esophagitis is a chronic illness that is treated with steroids and acid-suppressing medications such proton pump inhibitors. Steroids aid in the reduction of inflammation. Topical steroids come in the form of an inhaler or a liquid. People with substantial swallowing issues or weight loss may be offered oral steroids. Proton pump inhibitors reduce inflammation and aid with reflux symptoms. Eosinophilic esophagitis (EoE) is a persistent esophageal immune system disorder. In EoE, the inner lining of the oesophagus is lined with a large number of white blood cells called eosinophils. The oesophagus tissue can become inflamed or injured as a result of this buildup, which can be caused by food, allergens, or acid reflux. Adults with eosinophilic esophagitis experience difficulty swallowing, impaction, chest pain that is often centrally situated and does not react to antacids, and backflow of undigested food. In clinical studies, drug candidates being developed and researched for the treatment of eosinophilic esophagitis have showed encouraging results. As a result, regulatory agencies such as the US Food and Medication Administration (FDA) are giving these drug candidates designations. Over the forecast period, this is expected to boost market growth. Various public and medical community awareness initiatives have been designed and implemented to educate the public and medical community about eosinophil-associated illnesses, which is expected to drive market growth over the forecast period.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Eosinophilic Esophagitis (EoE) Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Eosinophilic Esophagitis (EoE) Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • GlaxoSmithKline plc.
  • Ellodi Pharmaceuticals
  • EsoCap AG
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • AstraZeneca Plc.
  • Sanofi S.A.
  • Arena Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Revolo Biotherapeutics
  • Allakos Inc.
  • Bristol-Myers Squibb Co.
  • Calypso Biotech
  • DBV Technologies
  • Landos Biopharma, Inc.
  • Glenmark Pharmaceuticals
  • Alkem Laboratories Ltd.
  • Quorum Innovations LLC
  • Dr. Falk Pharma GmbH

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Corticosteroids
    • Budesonide
      • Jorveza
      • Off-label budesonide
    • Fluticasone
  • Proton Pump Inhibitor (PPI)
    • Omeprazole
    • Esomeprazole
    • Others
  • Late Stage Pipeline Drugs
    • Dupixent
    • APT-1011
    • Lirentelimab (AK002)
    • Cendakimab
    • Etrasimod
    • TAK-721
    • Omilancor (BT-11)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Eosinophilic Esophagitis (EoE) Market By Drug Class, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Eosinophilic Esophagitis (EoE) Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Eosinophilic Esophagitis (EoE) Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Eosinophilic Esophagitis (EoE) Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Eosinophilic Esophagitis (EoE) Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Corticosteroids
         1.1. Budesonide
          1.1.1. Jorveza
          1.1.2. Off-label budesonide
         1.2. Fluticasone
        2. Proton Pump Inhibitor (PPI)
         2.1. Omeprazole
         2.2. Esomeprazole
         2.3. Others
        3. Late Stage Pipeline Drugs
         3.1. Dupixent
         3.2. APT-1011
         3.3. Lirentelimab (AK002)
         3.4. Cendakimab
         3.5. Etrasimod
         3.6. TAK-721
         3.7. Omilancor (BT-11)

  • 8.   Eosinophilic Esophagitis (EoE) Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 9.   North America Eosinophilic Esophagitis (EoE) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Eosinophilic Esophagitis (EoE) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Eosinophilic Esophagitis (EoE) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Eosinophilic Esophagitis (EoE) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. GlaxoSmithKline plc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Ellodi Pharmaceuticals
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. EsoCap AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Teva Pharmaceutical Industries Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Cipla Limited
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Sun Pharmaceutical Industries Limited
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. AstraZeneca Plc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Sanofi S.A.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Arena Pharmaceuticals, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Takeda Pharmaceutical Company Limited
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Revolo Biotherapeutics
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Allakos Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Bristol-Myers Squibb Co.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Calypso Biotech
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. DBV Technologies
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Landos Biopharma, Inc.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Glenmark Pharmaceuticals
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Alkem Laboratories Ltd.
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Quorum Innovations LLC
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Dr. Falk Pharma GmbH
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients